Perspectum and the associated logos are trademarks of Perspectum.

Perspectum is a precision health company pioneering advanced imaging technologies and AI-powered diagnostics to improve detection, risk stratification, and monitoring of chronic metabolic and liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Through its non-invasive, imaging-based solutions, Perspectum is reshaping how clinicians identify and manage patients at risk of progressive liver damage.

At the core of Perspectum’s platform is LiverMultiScan®, an FDA-cleared, MRI-based diagnostic that quantifies liver fat, iron, and fibroinflammatory activity—key biomarkers for assessing disease severity in MASLD/MASH. Unlike traditional biopsies, LiverMultiScan provides a safe, reproducible, and patient-friendly alternative that enables early diagnosis and ongoing treatment assessment in both clinical practice and drug development.

Perspectum’s broader pipeline includes integrated tools for multi-organ metabolic assessment, such as CoverScan®, which evaluates liver, heart, pancreas, and other organs simultaneously—highlighting the systemic nature of metabolic disease. These innovations support a more holistic, preventative approach to care, particularly in patients with overlapping conditions like type 2 diabetes, obesity, and cardiovascular disease.

With its cutting-edge technology and commitment to improving outcomes through better diagnostics, Perspectum plays a pivotal role in the evolving MASLD/MASH care model. By empowering clinicians with more accurate and timely insights, the company aims to enhance clinical decision-making, reduce reliance on invasive procedures, and ultimately drive earlier, more effective interventions in liver health.